Tau as a therapeutic target in neurodegenerative disease
- 9 July 2012
- journal article
- review article
- Published by Elsevier in Pharmacology & Therapeutics
- Vol. 136 (1), 8-22
- https://doi.org/10.1016/j.pharmthera.2012.07.001
Abstract
No abstract availableKeywords
This publication has 159 references indexed in Scilit:
- Proline Isomer-Specific Antibodies Reveal the Early Pathogenic Tau Conformation in Alzheimer's DiseaseCell, 2012
- Heat Shock Protein 70 Prevents both Tau Aggregation and the Inhibitory Effects of Preexisting Tau Aggregates on Fast Axonal TransportBiochemistry, 2011
- Progression of Tau Pathology in Cholinergic Basal Forebrain Neurons in Mild Cognitive Impairment and Alzheimer's DiseaseThe American Journal of Pathology, 2011
- The characterization of microtubule-stabilizing drugs as possible therapeutic agents for Alzheimer's disease and related tauopathiesPharmacological Research, 2010
- The amino terminus of tau inhibits kinesin‐dependent axonal transport: Implications for filament toxicityJournal of Neuroscience Research, 2008
- Potent inhibition of tau fibrillization with a multivalent ligandBiochemical and Biophysical Research Communications, 2007
- Detection and quantification of tau aggregation using a membrane filter assayAnalytical Biochemistry, 2007
- Potency of a tau fibrillization inhibitor is influenced by its aggregation stateArchives of Biochemistry and Biophysics, 2007
- Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐BAnnals of Neurology, 2004
- Tau Polymerization: Role of the Amino TerminusBiochemistry, 2003